• Products
  • Preclinical
  • Phase 1/2
  • Phase 3
  • Marketed
  • TPM®/Diclofenac GelSigns and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitisNovartis & Themis Medicare have rights for India; Themis Medicare has rights for 16 additional territories*
  • TPM®/Oxymorphone Transdermal Matrix PatchModerate to severe chronic painTerumo Corporation has signed a non-binding Term Sheet for Japan
  • TPM®/Oxycodone Transdermal Matrix PatchTBD; localized pain conditonsNone
  • TPM®/Tretinoin GelAcne vulgarisNone
  • TPM®/Propofol Injectable EmulsionAnesthesiaJoint R&D Partnership with Terumo Corporation; Terumo has Japanese rights
  • TPM®/Daptomycin Lyophilized Powder for IV InjectionComplicated skin and skin structure infections (cSSSI)Mylan has worldwide marketing rights

Note: all development phases are not applicable for 505(b)2 regulatory filings in the USA, or similar filings in other jurisdictions
* Armenia, Belarus, Georgia, Kazakhstan, Kenya, Kyrgyzstan, Moldova, Philippines, Rwanda, Sri Lanka, Tanzania, Turkmenistan, Uganda, Ukraine, Uzbekistan and Vietnam